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Purpose: The aim of the study was to examine the discontinuation rate of hormonal contra-
ception with estradiol valerate (E2V) and dienogest (DNG).
Patients and methods: We collected data at the Family Planning Clinics of the
Departments of Obstetrics and Gynecology of Pisa and Cagliari. We included in the analysis
354 consecutive women using oral contraceptive pills containing E2V and DNG. We
analyzed the rate and the reason for discontinuation, classifying the reasons in 5 categories:
1) minor side effects, 2) adverse events, 3) other events not directly caused by the drug or
conditions for which the pill could represent a risk factor, 4) no compliance with the method
and 5) no further need.
Results: Of the 354 women examined, 50.8% had discontinued E2V/DNG pill. Excluding
women who stopped the pill because of no further need (10.5%), 27.4% discontinued
because of minor side effects, 1.7% discontinued for adverse events, 9.9% because of
other events not directly caused by the drug or conditions for which the pill could represent
a risk factor and 1.4% because of difﬁculties with compliance. Irregular bleedings were the
main reasons reported for discontinuation. The time to discontinuation for irregular bleedings
was signiﬁcantly (p<0.02) longer in adults than in adolescents and slightly but not signiﬁ-
cantly longer in women who received information about this possible effect.
Conclusion: Unacceptable cycle control was the principal cause of discontinuation of pill
with E2V and DNG. An appropriate information about this possible effect may improve
adherence to this combined oral contraceptive.
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Introduction
The most important problem of combined oral contraceptives (COCs) is still the
high rate of discontinuation due to side effects. Since 2010, COCs containing 17β-
estradiol (E2-COCs) have been introduced in the market. The well-known pharma-
cokinetic properties of estradiol (E2) and E2 valerate (E2V)1 contribute to decreas-
ing the incidence of some hormone withdrawal-associated symptoms, possibly
reducing the rate of discontinuation.2,3 Moreover, these preparations have negligible
effects on carbohydrate and lipid metabolism and hemostasis, showing a safer
proﬁle than COCs containing ethinylestradiol (EE-COCs).4–6 In fact, E2 exerts a
weaker impact on hepatic metabolism than EE and it is less potent in inducing
synthesis of hepatic proteins.1,7,8
There are two different formulations, the combined monophasic one containing
E2 and nomegestrol acetate and the quadriphasic formulation containing E2V
associated with dienogest (DNG).5,6,9–11
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The combination of E2V with a potent progestin like
DNG was formulated in order to obtain a better cycle
control than the one expected with E2.9 The extended
regimen of this combination and the stable levels of E2
throughout the cycle may reduce the incidence of some
minor side effects.3 In a Phase III study, the appearance of
irregular bleedings is similar to that of the pill with EE and
levonorgestrel (LNG), but with a higher incidence of
amenorrhea.10
Our study was designed to analyze in a real-life setting
the rate and causes of discontinuation with hormonal con-
traceptives containing E2V/DNG.
Methods
Study design
We collected data at the Family Planning Clinic of the
Department of Obstetrics and Gynecology of Pisa and
Cagliari University Hospital.
The pill considered for this study was the quadriphasic
compound containing E2V 1–3 mg plus DNG 2–3 mg. We
searched the patients in our databases of informatic med-
ical records among women who came to our clinics
between January 2014 and March 2018. We considered
the following eligible for the study: women who attended
our clinics and started the use of the pill after its prescrip-
tion in that period and women who attended our clinics in
that period and were already taking the pill because it has
been prescribed in our clinics before the period considered
(for these women we recorded their baseline information
before the start of the pill intake). In order to exclude
possible biases, we included in our analysis only women
who were ﬁrst-time users (ie, not switching from another
pill). E2V/DNG was administered using an E2 step-down
and a progestin step-up approach over 26 days (E2V 3 mg
on days 1 and 2, E2V 2 mg and DNG 2 mg on days 3–7,
E2V 2 mg and DNG 3 mg on days 8–24, E2V 1 mg on
days 25 and 26 and placebo on days 27 and 28).
We found 354 women, and we analyzed their clinical
charts. For baseline analysis, we collected information
about age and body mass index, educational level (divid-
ing it in “primary school” or “higher than primary school”)
and parity (nulliparous or parous) before the beginning of
the treatment. All women considered had complete base-
line information.
On March 2018, we evaluated if women were still
using the pill or if they discontinued it. We recorded the
time (expressed in total months of pill intake) and reason
for discontinuation and if the women received the infor-
mation about the possible side effects at the time of pre-
scription. In 19.7% of women, this information was not
present in the charts and we obtained it by phone.
We recorded the reasons for stopping in 5 categories:
1) minor side effects (ie, symptoms or events supposedly
related to the pill that are not life-threatening and do not
cause hospitalization, disability or permanent damage), 2)
adverse events (ie, undesirable symptoms or events suppo-
sedly related to the use of the pill that can have serious
outcomes and require a medical intervention), 3) other
events (ie, not life-threatening medical reasons not directly
caused by the drug or other conditions for which the pill
could represent a risk factor), 4) no compliance with the
method (ie, women who do not assume the pill in the
proper way) and 5) no further need.
The protocol was approved by the Ethics Committee of
the Departments of Obstetrics and Gynecology of Pisa
University Hospital (Pisa, Italy) and of Cagliari
University Hospital (Cagliari, Italy). All procedures per-
formed in the study were in accordance with the ethical
standards of the Committee on Institutional human experi-
mentation and with the Helsinki declaration of 1975, as
revised in 1983. Patients gave their written informed con-
sent to data collection and to the review of their anon-
ymous data for clinical publication.
Statistical analysis
All data are reported as mean±SD (M±SD) or as percen-
tage (%). We used the Kaplan–Meier analysis to evaluate
the time-to-event for discontinuation stratiﬁed according to
the reasons. We tested if the discontinuation rate between
adolescents and adults was different with the Chi-squared
test. We tested the differences in the time of discontinua-
tion for irregular bleeding between adolescents and adults
and between women who did and who did not receive the
information at the time of prescription with Mann–
Whitney U-test.
Statistical analysis was performed using Statistica
Software (Statsoft, Palo Alto, CA, USA).
Results
Weanalyzed 354 consecutivewomenwho received a prescrip-
tion of the quadriphasic compound containing E2Vand DNG.
The age range was 14–54 years. Eighty-ﬁve (24%) of them
were 20 years old or less. Table 1 reports the characteristics of
the population. One hundred and eighty (50.8%) of 354
women taking E2-COCs reported to have stopped COCs for
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some reason. The time until interruption of the hormonal
contraceptive ranged from 1 to 84months (15.2±17.5months).
Excluding women who stopped the pill, the remaining women
were still on contraception at the time of the interview from 23
±18.7 months (range 1–96 months). There is no difference in
the discontinuation rate between adolescents and adults
(44.7% vs 52.8%, p=0.19) and the mean time until disconti-
nuation was similar (14.5±16.6 vs 15.4±7.7 months).
Excluding women who stopped the pill because of no
further need (n=37; 10.5%), the most frequent reason for
discontinuation was the appearance of minor side effects
(n=97; 27.4%). Six women (1.7%) discontinued for
adverse events and 35 (9.9%) for other events supposedly
not directly caused by the drug or for other conditions for
which the pill could represent a risk factor. No compliance
for the method was reported by 5 women (1.4%). Most of
the women (N=152, 84.4%) interrupted in the ﬁrst 2 years
of pill intake.
Table 2 reports the analysis of minor side effects and
the rate of discontinuation. Some of the women who
stopped for minor side effects suffered from two or more
side effects contemporarily. The most frequent minor side
effect was an unacceptable bleeding pattern (n=53;
15.0%), followed by headache (4.0%), mood instability
(3.7%), symptoms of hyperandrogenism (3.1%), weight
gain (2.5%) and breast tenderness (2.0%). Dysmenorrhea
was reported by 0.6% and decreased libido by 0.3% of E2-
COCs users.
When unacceptable bleeding pattern was the reason, 31
women (58.5%) interrupted the medication within 6
months from the beginning, the others after a longer period
(until 3 years). The time of interruption for irregular bleed-
ing was signiﬁcantly shorter in the adolescent group (5.2
±5.2 months) than in the adult group (10±8.3 months;
p<0.02) (Figure 1). Twenty-ﬁve women (47.2%) who
interrupted for an unacceptable bleeding pattern reported
that they had not received information about the possibility
that amenorrhea and spotting might occur during treatment
with pills with E2. The mean duration of pill intake in
women who received information at the time of
Table 1 Baseline demographic characteristics of the women
(N=354)
Characteristics N %
Age (years)
≤17 31 8.8
18–25 120 33.9
26–34 83 23.4
35–42 62 17.5
≥43 58 16.4
BMI
≤19 34 9.6
19.1–25 245 69.2
25.1–33 61 17.2
>33 14 4
Educational level
Primary school 2 0.6
Higher than primary school 352 99.4
Parity
Nulliparous 168 47.5
Parous 186 52.5
Abbreviation: BMI, body mass index.
Table 2 Minor side effects (ie, symptoms or events supposedly
related to the pill that are not life-threatening and do not cause
hospitalization, disability or permanent damage) reported as
cause of discontinuation of the pill with estradiol valerate and
dienogest. The results are expressed as a percentage of number
of women who discontinued for such effects on the total number
(354) of women examined. The absolute number of women who
suffered from each side effect is shown in brackets. Some women
reported more than one minor side effect contemporarily
Reported symptom % (N)
Menstrual irregularities 15.0 (53)
Weight gain and water retention 2.5 (9)
Headache 4.0 (14)
Mood alterations 3.7 (13)
Acne, hirsutism, alopecia 3.1 (11)
Decreased libido 0.3 (1)
Breast tenderness 2.0 (7)
Dysmenorrhea 0.6 (2)
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Figure 1 Interruption of pill with estradiol valerate and dienogest because of
unacceptable bleeding according to the age of women. The time (M ± SD) from
beginning of pill intake to discontinuation in adolescents was signiﬁcantly shorter
than in the adult group. *: p<0.02.
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prescription was slightly but not signiﬁcantly longer (11
±9.7 months) than women who did not (7±4.9 months,
p=0.06) (Figure 2).
Adverse events and all the other medical reasons for
discontinuation are listed in Table 3. Among the 6 patients
that discontinued because of a severe adverse event, 2
patients had a deep-venous thrombosis (VT). In one case
VT occurred after 3 months from the onset of the pill. A
more detailed analysis revealed that this woman had a
factor V Leiden deﬁciency. In the other patient, VT
occurred after surgery. In 3 cases women reported a super-
ﬁcial venous phlebitis. The woman who reported an epi-
sode of depression already had a diagnosis of bipolar
disorder.
Discussion
This is a small observational study undertaken to evaluate the
discontinuation rate of hormonal contraception with E2V/
DNG in a real-life setting during a random period of 4 years.
The aim was to test the supposed improved compliance of
E2-COCs toward hormonal contraception. Our study shows
that the percentage of women discontinuing E2-COCs is still
high, but most of the patients were still taking the pill after 1
year (65%), suggesting the clinical acceptability of the com-
pound in young and adult women. In a previous study, we
reported that one-third of users may discontinue pills con-
taining 30 mcg or 20 mcg of EE, mainly due to minor side
effects, with irregular bleedings, weight gain and headache
being the main reasons reported for discontinuation.12 The
unacceptable bleeding pattern is the principal cause for dis-
continuation also for E2-COCs, whereas the incidence of
other minor side effects (weight gain, headache, etc.) was
very low. In a European Phase III trial, with 20 cycles of
observation, only 2.5% of women discontinued treatment
prematurely due to bleeding irregularities.13 Our data are
higher than the above, but quite similar to those of a large
clinical study performed in a real-life setting (27.7%).14 The
discontinuation rate for irregular bleedings that we observed
with E2-COCs was higher than that (5.3%) observed in a
previous study performed on women who took pills with 20
mcg of EE,12 possibly due to the higher stability of the
endometrium when synthetic estrogens were used.15 This
may be considered an expected ﬁnding since the progestin-
induced stimulation of endometrial 17 beta-hydroxysteroid
dehydrogenase causes a rapid local inactivation of E2.7,9,15
By contrast, EE cannot be metabolized by this enzyme, as the
ethinyl group blocks the oxidation of the 17 beta-hydroxy
group. It is noteworthy that the mean time to discontinuation
is about 9 months, suggesting that in spite of an unsatisfac-
tory bleeding pattern, women, in general, did not experience
problematic bleedings inducing them to quickly interrupt the
pill and women wanted to continue with the E2 pill on the
whole.
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Figure 2 Interruption of pill with estradiol valerate and dienogest for unacceptable
cycle control. Women who were informed about the possible appearance of
irregular bleedings interrupted after a longer period than subjects who did not
receive the information, but the difference was not signiﬁcant (p=0.06). Data are
expressed as M ± SD.
Table 3 Adverse events (ie, undesirable symptoms or events
supposedly related to the use of the pill that can have serious
outcomes and require a medical intervention) and other events
(ie, not life-threatening medical reasons not directly caused by
the drug or other conditions for which the pill could represent a
risk factor) reported as cause of discontinuation of hormonal
contraception with estradiol valerate and dienogest. The results
are expressed as a percentage of total number of women who
discontinued for such effects on the total number (354) of
women examined. The absolute number of women who reported
each symptom is shown in brackets
Reported symptom % (N)
Adverse events 1.7 (6)
Deep vein thrombosis 0.6 (2)
Depression 0.3 (1)
Phlebopathies 0.8 (3)
Other events 9.9 (35)
Cramps and leg pain 0.6 (2)
Hyperhomocysteinemia 0.6 (2)
Decreased blood pressure 0.6 (2)
Familiarity for deep vein thrombosis 0.6 (2)
Tingling upper limb 0.3 (1)
Hemorrhoids pain 0.6 (2)
Myoma increase 0.3 (1)
Benign breast lesions 1.1 (4)
Familiarity for breast cancer 0.3 (1)
Medical advice 5.0 (18)
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Adolescents stopped the pill for irregular bleeding
more and quicker than adults. This ﬁnding is very impor-
tant in clinical practice and must be taken into considera-
tion at the time of prescription. Irregular bleedings and
amenorrhea sometimes may arise concerns about their
possible negative meanings and adolescents may be more
affected by this concern.
Our data also show that the interruption for a low cycle
control was mainly noted in users who at the time of pre-
scription had not been informed about the possibility that the
use of E2-COCs may be associated with an increased rate of
absent withdrawal bleeding or unscheduled bleeding. Our
study had not been performed to evaluate the importance
and the value of counseling in inﬂuencing the rate of dis-
continuation. Women were only asked if they received the
information about possible changes in their cycles, ie, ame-
norrhea or spotting.Womenwho had not been informedwere
more likely to interrupt the pill within 6 months, whereas
womenwho had been informed stopped after a longer period,
with a mean duration of pill intake before discontinuation of
about 12months. The difference is not statistically signiﬁcant
because of the small sample of women analyzed. However,
the slightly longer time of pill intake in womenwho had been
informed underlines the importance of giving information at
the time of prescription, making a detailed counseling about
possible side effects and their meaning and focusing on
possible changes in the bleeding pattern.
The incidence of major side effects was very low: we
observed two cases of VT, one because of thrombophilia
and the other after surgery, underlining the relevance of
this possible complication also in users of the pill with E2.
No other important major side effects were reported, even
in those cases where discontinuation had been suggested
by a physician for medical reasons.
The principal weakness is that this is a retrospective
study. In fact, the study had not been designed to prospec-
tively evaluate in a population of ﬁrst pill users if E2-
COCs had a different discontinuation rate compared to
EE-COCs and if an adequate counseling at the time of
prescription could modify the behavior of the pill users
and then the results. Data had been collected looking into
the charts containing all information collected during fol-
low-up visits of women who in a frame of time had their
ﬁrst prescription of a E2-pill in our outpatient clinics.
In conclusion, in our study, the major reason for discon-
tinuation of E2-COCs was the low cycle control. However,
the discontinuation occurred after a mean time longer than 1
year. The incidence of other side effects was very low.
Moreover, our data suggest that a proper information may
improve adherence, reducing the premature pill discontinua-
tion. This further emphasizes the role of the physician at the
time of prescription in giving adequate information about all
possible side effects related to E2-COCs use and in particular
the possible changes in the bleeding pattern. Further larger
studies are warranted in order to conﬁrm the role of physician
counseling on E2-COC adherence.
Abbreviation list
COCs, combined oral contraceptives; DNG, dienogest; E2,
17β-estradiol; E2-COCs, combined oral contraceptives
containing 17β-estradiol; E2V, estradiol valerate; EE, ethi-
nylestradiol; EE-COCs, combined oral contraceptives con-
taining ethinylestradiol; LNG, levonogestrel; VT, venous
thrombosis.
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